CL2004000192A1 - Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja. - Google Patents
Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.Info
- Publication number
- CL2004000192A1 CL2004000192A1 CL200400192A CL2004000192A CL2004000192A1 CL 2004000192 A1 CL2004000192 A1 CL 2004000192A1 CL 200400192 A CL200400192 A CL 200400192A CL 2004000192 A CL2004000192 A CL 2004000192A CL 2004000192 A1 CL2004000192 A1 CL 2004000192A1
- Authority
- CL
- Chile
- Prior art keywords
- aminopirimidine
- prevention
- prepare
- hiv infection
- medicinal product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0301291 | 2003-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2004000192A1 true CL2004000192A1 (es) | 2005-03-18 |
Family
ID=32842658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200400192A CL2004000192A1 (es) | 2003-02-07 | 2004-02-04 | Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20070021449A1 (es) |
| EP (1) | EP1597237B1 (es) |
| JP (2) | JP5602333B2 (es) |
| KR (2) | KR101185048B1 (es) |
| CN (2) | CN102151270A (es) |
| AP (1) | AP2065A (es) |
| AU (1) | AU2004210081B2 (es) |
| BR (1) | BRPI0407329A (es) |
| CA (1) | CA2513527C (es) |
| CL (1) | CL2004000192A1 (es) |
| EA (1) | EA011164B1 (es) |
| ES (1) | ES2598404T3 (es) |
| HR (1) | HRP20050688B1 (es) |
| IL (1) | IL170114A (es) |
| MX (1) | MXPA05008364A (es) |
| MY (1) | MY176490A (es) |
| NO (1) | NO334178B1 (es) |
| NZ (1) | NZ541902A (es) |
| PL (1) | PL227577B1 (es) |
| UA (1) | UA80601C2 (es) |
| WO (1) | WO2004069812A1 (es) |
| ZA (1) | ZA200506253B (es) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| NZ537752A (en) | 2002-07-29 | 2006-12-22 | Rigel Pharmaceuticals Inc | Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases |
| CN102151270A (zh) | 2003-02-07 | 2011-08-17 | 詹森药业有限公司 | 预防hiv感染的嘧啶衍生物 |
| SG145698A1 (en) | 2003-07-30 | 2008-09-29 | Rigel Pharmaceuticals Inc | Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds |
| WO2005016894A1 (en) * | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| EP1809614B1 (en) | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazine inhibitors of kinases |
| WO2007050087A1 (en) | 2004-08-25 | 2007-05-03 | Ardea Biosciences, Inc. | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS |
| SG155246A1 (en) | 2004-08-25 | 2009-09-30 | Ardea Biosciences Inc | S-TRIAZOLYL α-MERCAPTOACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE |
| NZ553492A (en) | 2004-08-25 | 2010-11-26 | Targegen Inc | Triazole derivatives and methods of use |
| ES2384715T3 (es) * | 2004-09-02 | 2012-07-11 | Janssen Pharmaceutica Nv | Fumarato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo |
| DK1632232T6 (da) * | 2004-09-02 | 2022-04-19 | Janssen Pharmaceutica Nv | Salt af 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]¬amino]¬benzonitril |
| JP4958786B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| WO2006101521A2 (en) | 2004-09-20 | 2006-09-28 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| BRPI0515489A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase |
| CN101084211A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为治疗剂的用途 |
| BRPI0515478A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase |
| EP2316458A1 (en) | 2004-09-20 | 2011-05-04 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
| TW200626592A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| EP1814878B1 (en) | 2004-11-24 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
| NZ555947A (en) | 2005-01-19 | 2010-11-26 | Rigel Pharmaceuticals Inc | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| TWI457136B (zh) | 2005-04-04 | 2014-10-21 | Tibotec Pharm Ltd | Ｈｉｖ-感染之預防 |
| WO2006122003A2 (en) | 2005-05-05 | 2006-11-16 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
| EP2029138A1 (en) | 2005-06-03 | 2009-03-04 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| JP5225079B2 (ja) | 2005-06-08 | 2013-07-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| BRPI0618179A2 (pt) | 2005-11-01 | 2011-08-23 | Targegen Inc | inibidores de biaril meta pirimidina de cinases |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| USRE50189E1 (en) | 2006-01-20 | 2024-10-29 | Janssen Sciences Ireland Unlimited Company | Long term treatment of HIV-infection with TMC278 |
| CA2645959C (en) * | 2006-03-30 | 2016-05-17 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines |
| WO2008058285A2 (en) | 2006-11-09 | 2008-05-15 | Ardea Biosciences, Inc. | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors |
| AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| DK2146779T3 (en) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
| WO2009067166A2 (en) * | 2007-11-20 | 2009-05-28 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
| RS53569B1 (en) | 2007-11-27 | 2015-02-27 | Ardea Biosciences, Inc. | NEW COMPOUNDS AND COMPOSITIONS, AND PROCEDURES FOR USE |
| WO2009079412A2 (en) | 2007-12-14 | 2009-06-25 | Ardea Biosciences Inc. | Reverse transcriptase inhibitors |
| US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| EP2440559B1 (en) | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
| BR112013003388A2 (pt) | 2010-08-10 | 2016-07-12 | Celgene Avilomics Res Inc | sal de besilato de um inibidor de btk |
| KR101692407B1 (ko) * | 2010-08-19 | 2017-01-04 | 삼성전자주식회사 | 라인 패턴 구조물의 형성 방법 |
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| KR101954593B1 (ko) | 2010-11-01 | 2019-03-06 | 셀젠 카르 엘엘씨 | 헤테로사이클릭 화합물 및 이의 용도 |
| ES2635713T3 (es) | 2010-11-01 | 2017-10-04 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
| CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| JP5957003B2 (ja) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | 変異体選択的ｅｇｆｒ阻害剤およびその使用 |
| WO2013063401A1 (en) | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
| SG11201405691WA (en) | 2012-03-15 | 2014-10-30 | Celgene Avilomics Res Inc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
| PT2825042T (pt) | 2012-03-15 | 2018-11-16 | Celgene Car Llc | Sais de um inibidor de cinases do recetor do fator de crescimento epidérmico |
| GB201204756D0 (en) * | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| EP2935226A4 (en) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | HETEROARYL COMPOUNDS AND USES THEREOF |
| PE20151274A1 (es) | 2013-02-08 | 2015-09-12 | Celgene Avilomics Res Inc | Inhibidores de erk y sus usos |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| KR102440843B1 (ko) | 2014-04-01 | 2022-09-29 | 머크 샤프 앤드 돔 엘엘씨 | Hiv 역전사효소 억제제의 전구약물 |
| US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
| WO2016031651A1 (ja) * | 2014-08-29 | 2016-03-03 | 花王株式会社 | 難溶解性ポリフェノール類を含有する固体分散体の製造方法 |
| WO2017139001A2 (en) * | 2015-11-24 | 2017-08-17 | Droneshield, Llc | Drone detection and classification with compensation for background clutter sources |
| CN106749203B (zh) * | 2016-11-28 | 2020-04-10 | 洛阳聚慧医药科技有限公司 | 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用 |
| CN106905244B (zh) * | 2017-02-27 | 2019-08-16 | 武汉工程大学 | 二芳基嘧啶-二酮酸类杂合型hiv-1抑制剂及其制备方法 |
| WO2019140365A1 (en) | 2018-01-12 | 2019-07-18 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| WO2019199756A1 (en) | 2018-04-09 | 2019-10-17 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| MX2022007376A (es) | 2019-12-20 | 2022-09-02 | Tenaya Therapeutics Inc | Fluoroalqull-oxadiazoles y sus usos. |
| CN111004215B (zh) * | 2019-12-22 | 2022-08-09 | 华北理工大学 | 2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3459732A (en) * | 1967-03-22 | 1969-08-05 | Corn Products Co | Cyclodextrin carbamates |
| AU596272B2 (en) * | 1987-02-25 | 1990-04-26 | Trustees Of Columbia University In The City Of New York, The | Method of inhibiting the transmission of aids virus |
| US4952411A (en) * | 1987-02-25 | 1990-08-28 | Trustees Of Columbia University In The City Of New York | Method of inhibiting the transmission of AIDS virus |
| US5667492A (en) * | 1994-10-07 | 1997-09-16 | Columbia Laboratories, Inc. | Use and composition of an anti-sexually transmitted diseases formulation |
| US5691364A (en) * | 1995-03-10 | 1997-11-25 | Berlex Laboratories, Inc. | Benzamidine derivatives and their use as anti-coagulants |
| GB9507883D0 (en) * | 1995-04-18 | 1995-05-31 | Retroscreen Ltd | Compounds |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| JP3310299B2 (ja) | 1995-11-23 | 2002-08-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 溶融−押し出しにより調製されるシクロデキストリンの固体混合物 |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| DE69905306T2 (de) * | 1998-03-27 | 2003-11-27 | Janssen Pharmaceutica N.V., Beerse | HIV hemmende Pyrimidin Derivate |
| HU227453B1 (en) | 1998-11-10 | 2011-06-28 | Janssen Pharmaceutica Nv | Hiv replication inhibiting pyrimidines, and pharmaceutical compositions containing them |
| CN1348370A (zh) | 1999-04-15 | 2002-05-08 | 布里斯托尔-迈尔斯斯奎布公司 | 环状蛋白酪氨酸激酶抑制剂 |
| US6472410B1 (en) * | 1999-06-11 | 2002-10-29 | Merck & Co., Inc. | N-cyclopentyl modulators of chemokine receptor activity |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| IL148801A0 (en) * | 1999-09-24 | 2002-09-12 | Janssen Pharmaceutica Nv | Antiviral compositions |
| WO2001085700A2 (en) | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
| US6596729B2 (en) * | 2000-07-20 | 2003-07-22 | Bristol-Myers Squibb Company | Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors |
| CA2439820A1 (en) * | 2001-03-02 | 2002-09-12 | Smithkline Beecham Corporation | Benzophenones as inhibitors of reverse transcriptase |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| TW200306192A (en) * | 2002-01-18 | 2003-11-16 | Bristol Myers Squibb Co | Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors |
| AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| WO2004050068A1 (en) | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| CN102151270A (zh) | 2003-02-07 | 2011-08-17 | 詹森药业有限公司 | 预防hiv感染的嘧啶衍生物 |
-
2004
- 2004-02-04 CN CN2011100443222A patent/CN102151270A/zh active Pending
- 2004-02-04 KR KR1020057013837A patent/KR101185048B1/ko active IP Right Grant
- 2004-02-04 BR BR0407329-0A patent/BRPI0407329A/pt not_active Application Discontinuation
- 2004-02-04 ES ES04707937.1T patent/ES2598404T3/es not_active Expired - Lifetime
- 2004-02-04 AP AP2005003366A patent/AP2065A/en active
- 2004-02-04 NZ NZ541902A patent/NZ541902A/en not_active IP Right Cessation
- 2004-02-04 CN CNA2004800034604A patent/CN1747937A/zh active Pending
- 2004-02-04 JP JP2006501729A patent/JP5602333B2/ja not_active Expired - Lifetime
- 2004-02-04 PL PL378144A patent/PL227577B1/pl unknown
- 2004-02-04 EP EP04707937.1A patent/EP1597237B1/en not_active Expired - Lifetime
- 2004-02-04 AU AU2004210081A patent/AU2004210081B2/en not_active Expired
- 2004-02-04 WO PCT/EP2004/001011 patent/WO2004069812A1/en active Application Filing
- 2004-02-04 CA CA2513527A patent/CA2513527C/en not_active Expired - Lifetime
- 2004-02-04 CL CL200400192A patent/CL2004000192A1/es unknown
- 2004-02-04 US US10/544,735 patent/US20070021449A1/en not_active Abandoned
- 2004-02-04 MX MXPA05008364A patent/MXPA05008364A/es active IP Right Grant
- 2004-02-04 EA EA200501265A patent/EA011164B1/ru unknown
- 2004-02-04 KR KR1020117026076A patent/KR20110132482A/ko not_active Application Discontinuation
- 2004-02-05 MY MYPI20040342A patent/MY176490A/en unknown
- 2004-04-02 UA UAA200508362A patent/UA80601C2/uk unknown
-
2005
- 2005-08-01 HR HRP20050688AA patent/HRP20050688B1/hr not_active IP Right Cessation
- 2005-08-04 ZA ZA200506253A patent/ZA200506253B/xx unknown
- 2005-08-04 IL IL170114A patent/IL170114A/en active IP Right Grant
- 2005-09-06 NO NO20054143A patent/NO334178B1/no not_active IP Right Cessation
-
2009
- 2009-09-25 US US12/567,051 patent/US8828982B2/en active Active
-
2014
- 2014-05-21 JP JP2014105248A patent/JP5799133B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2004000192A1 (es) | Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja. | |
| AP2006003514A0 (en) | Piperazine derivatives for the treatment of HIV infections. | |
| IT1318682B1 (it) | Procedimento integrato per la preparazione di ossidi olefinici. | |
| WO2005053612A3 (en) | Micellar systems useful for delivery of lipophilic or hydrophobic compounds | |
| MA27018A1 (fr) | Forme dosifiee pharmaceutique de mesylate de nelfinavir amorphe. | |
| AR028423A1 (es) | Inhibidores de la replicacion del hiv | |
| ITTO20000779A0 (it) | Composizioni farmaceutiche. | |
| BR0205721A (pt) | Formulações de oximorfona de liberação controlada | |
| IT1318649B1 (it) | Composizioni farmaceutiche per il trattamento di mucositi e stomatiti. | |
| MXPA03001425A (es) | Compuestos farmaceuticos. | |
| FI20011889A (fi) | Menetelmä ksylitolin valmistamiseksi | |
| PT1355906E (pt) | Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas | |
| CL2004001421A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor. | |
| ITMI20001695A0 (it) | Procedimento per la preparazione di composizioni organico-sili-coniche. | |
| BR0111039B1 (pt) | processo para preparaÇço de 2-cloro-5-clorometil-1,3-tiazol. | |
| ITRM20010293A0 (it) | Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore. | |
| ITUD20030196A1 (it) | Procedimento per la preparazione di dosaggi farmaceutici contenenti molteplici principi attivi. | |
| MXPA03001857A (es) | Composicones medicinales. | |
| ES1048844Y (es) | Cupon precinto desprendible de cajas de medicamentos. | |
| ITRM20030442A0 (it) | Composizione farmaceutica (stressen) per il trattamento di iperomocisteinemia. | |
| ES1047686Y (es) | Mecanismo de bloqueo del resbalon para picaportes. | |
| ES1053798Y (es) | Dispositivo para la dosificacion de liquidos. | |
| ITMI20001600A0 (it) | Procedimento per la preparazione di 5-amino-4-alo-3-alchil isossazoli. | |
| IT1320253B1 (it) | Composizione farmaceutica per il trattamento della malaria. | |
| ITTO20000397A0 (it) | Procedimento perfezionato per la preparazione di 4-alchil-3-alcossianiline. |